Health News

SanBio Inc. announced that the United States Food and Drug Administration (FDA) has approved the clinical testing of their SB623 regenerative medicine product in patients suffering from disability caused by cerebral stroke. SB623 is derived from bone marrow stromal cells (MSCs) isolated from healthy adult donors…

Read more

Filed under: Pharmacy News
Tags: donors, Drug, medicine, Pharmacy

Related posts

• Global Fund to draw up action plan against drug theft, invites stakeholders to participate (0)
  The Global Fund to Fight AIDS, Tuberculosis and Malaria on Friday appealed to international donors to join them in an effort to fight medicine theft, SAPA/News24 reports. Read more [tags] Pharmacy News [/tags]
  
  
• Biobanking Americas Conference 7-9 June, 2011, Boston (0)
  The future for next generation drug discovery and personalised medicines 7th - 9th June 2011, Hilton Boston/Financial District, Boston, USA An estimated $1bn has been invested in the biobanking industry within the last ten years. At least 179 biobanks with 345,000 donors exist in the US, most of which were established in [...]
  
  
• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]
  
  
• Zoologists search sea for drugs of the future (0)
  No matter how sophisticated modern medicine becomes, common ailments like fungal infections can outrun the best of the world's antibiotics. Read more [tags] Pharmacy News [/tags]
  
  
• Zogenix, Desitin receive MAA approval for SUMAVEL DosePro in Germany and the UK (0)
  Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of [...]